

# Chronic Pulmonary Infections Market to Reach New Heights in Growth by 2032, DelveInsight Predicts

*DelveInsight's Chronic Pulmonary Infections Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.*

LAS VEGAS, NV, UNITED STATES,  
January 28, 2025 /EINPresswire.com/ --

DelveInsight's "Chronic Pulmonary Infections Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth

understanding of the Chronic

Pulmonary Infections, historical and forecasted epidemiology as well as the Chronic Pulmonary Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pulmonary Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Chronic Pulmonary Infections Market Forecast](#)

Some of the key facts of the Chronic Pulmonary Infections Market Report:

- The Chronic Pulmonary Infections market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology firm specializing in high-purity, pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial pathogens, has announced promising topline results from its Phase 2 "Tailwind" trial. The study evaluated AP-PA02, an innovative inhaled multi-phage therapy, for treating chronic pulmonary *Pseudomonas aeruginosa* ("P. aeruginosa") infections in patients with non-cystic fibrosis bronchiectasis ("NCFB").
- In July 2024, Armata Pharmaceuticals concluded patient enrollment for its Phase II Tailwind study, focused on evaluating the inhaled bacteriophage therapy AP-PA02 for treating chronic



Chronic Pulmonary Infections Market Forecast

pulmonary Pseudomonas infections. This critical trial is designed to investigate the safety, tolerability, and effectiveness of AP-PA02 in individuals with non-cystic fibrosis bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.

- Key Chronic Pulmonary Infections Companies: Armata Pharmaceuticals, ContraFect, antibacterial agents Sequoia Sciences, Infex Therapeutics, Aridis Pharmaceuticals, Respirion Pharmaceuticals, BiomX, and others
- Key Chronic Pulmonary Infections Therapies: CF 370, Research programme, RESP X, AR-501, RSP-1502, BX 004, AP-PA02, and others
- The Chronic Pulmonary Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pulmonary Infections pipeline products will significantly revolutionize the Chronic Pulmonary Infections market dynamics.

### Chronic Pulmonary Infections Overview

Chronic pulmonary infections refer to persistent or long-lasting infections affecting the respiratory system, particularly the lungs. These infections can be caused by various microorganisms such as bacteria, viruses, fungi, or parasites. Chronic pulmonary infections may lead to ongoing inflammation, damage to lung tissues, and respiratory symptoms.

Get a Free sample for the Chronic Pulmonary Infections Market Forecast, Size & Share Analysis Report:

[https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

### Chronic Pulmonary Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

### Chronic Pulmonary Infections Epidemiology Segmentation:

The Chronic Pulmonary Infections market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

- Total Prevalence of Chronic Pulmonary Infections
- Prevalent Cases of Chronic Pulmonary Infections by severity
- Gender-specific Prevalence of Chronic Pulmonary Infections
- Diagnosed Cases of Episodic and Chronic Chronic Pulmonary Infections

Download the report to understand which factors are driving Chronic Pulmonary Infections epidemiology trends @ [Chronic Pulmonary Infections Epidemiology Forecast](#)

## Chronic Pulmonary Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pulmonary Infections market or expected to get launched during the study period. The analysis covers Chronic Pulmonary Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Pulmonary Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

## Chronic Pulmonary Infections Therapies and Key Companies

- CF 370: ContraFect
- Research programme: antibacterial agents Sequoia Sciences
- RESP X: Infex Therapeutics
- AR-501: Aridis Pharmaceuticals
- RSP-1502: Respirion Pharmaceuticals
- BX 004: BiomX
- AP-PA02: Armata Pharma

## Chronic Pulmonary Infections Market Drivers

- Increasing Prevalence of Pulmonary Infections related to *Pseudomonas aeruginosa*, increase in research and developmental activities are some of the important factors that are fueling the Chronic *Pseudomonas aeruginosa* Pulmonary Infections Market.

## Chronic Pulmonary Infections Market Barriers

- However, side-effects associated with the treatment, high-cost associated with the disease and other factors are creating obstacles in the Chronic *Pseudomonas aeruginosa* Pulmonary Infections Market growth.

## Scope of the Chronic Pulmonary Infections Market Report

- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Pulmonary Infections Companies: Armata Pharmaceuticals, ContraFect, antibacterial agents Sequoia Sciences, Infex Therapeutics, Aridis Pharmaceuticals, Respirion Pharmaceuticals, BiomX, and others
- Key Chronic Pulmonary Infections Therapies: CF 370, Research programme, RESP X, AR-501, RSP-1502, BX 004, AP-PA02, and others
- Chronic Pulmonary Infections Therapeutic Assessment: Chronic Pulmonary Infections current

marketed and Chronic Pulmonary Infections emerging therapies

- Chronic Pulmonary Infections Market Dynamics: Chronic Pulmonary Infections market drivers and Chronic Pulmonary Infections market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Chronic Pulmonary Infections Unmet Needs, KOL's views, Analyst's views, Chronic Pulmonary Infections Market Access and Reimbursement

To know more about Chronic Pulmonary Infections companies working in the treatment market, visit @ [Chronic Pulmonary Infections Clinical Trials and Therapeutic Assessment](#)

## Table of Contents

1. Chronic Pulmonary Infections Market Report Introduction
2. Executive Summary for Chronic Pulmonary Infections
3. SWOT analysis of Chronic Pulmonary Infections
4. Chronic Pulmonary Infections Patient Share (%) Overview at a Glance
5. Chronic Pulmonary Infections Market Overview at a Glance
6. Chronic Pulmonary Infections Disease Background and Overview
7. Chronic Pulmonary Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pulmonary Infections
9. Chronic Pulmonary Infections Current Treatment and Medical Practices
10. Chronic Pulmonary Infections Unmet Needs
11. Chronic Pulmonary Infections Emerging Therapies
12. Chronic Pulmonary Infections Market Outlook
13. Country-Wise Chronic Pulmonary Infections Market Analysis (2019–2032)
14. Chronic Pulmonary Infections Market Access and Reimbursement of Therapies
15. Chronic Pulmonary Infections Market Drivers
16. Chronic Pulmonary Infections Market Barriers
17. Chronic Pulmonary Infections Appendix
18. Chronic Pulmonary Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

## About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/781084284>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.